Drug Trial Radar · NCT07777549
A Study of the Safety and Efficacy of TRTL-913 in Healthy Volunteers (Part A) and in Adults With Tinnitus (Part B)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 14, 2026
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Tortugas Neuroscience, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will consist of two parts. Double blind Part A will assess the safety, tolerability, and pharmacokinetics of 7 days of dosing in healthy adults, while open label Part B will evaluate the safety, tolerability, and efficacy of a 2-week treatment course in adults with tinnitus.
Conditions
- Tinnitus
Interventions
TRTL-913Drug
Participants will receive TRTL-913 capsules QD.
PlaceboDrug
Participants will receive TRTL-913 matching placebo capsules QD.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Up to Day 16
- Part B: Number of Participants With TEAEs and SAEsTime frame: Up to Day 21
- Part A: Number of Participants with Clinically Significant Change From Baseline in Vital Signs, Clinical Laboratory Values, and Electrocardiograms (ECGs)Time frame: Up to Day 16
- Part B: Number of Participants with Clinically Significant Change From Baseline in Vital Signs, Clinical Laboratory Values, and ECGsTime frame: Up to Day 21
- Part A: Number of Participants With Suicidal Ideation or Behavior as Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Day 16
- Part B: Number of Participants With Suicidal Ideation or Behavior as Assessed by the C-SSRSTime frame: Up to Day 21
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Newcastle, New South Wales, Australia · Not yet recruiting
Clinical Trial Site
Sydney, New South Wales, Australia · Not yet recruiting
Clinical Trial Site
Waitara, New South Wales, Australia · Not yet recruiting
Clinical Trial Site
Southport, Queensland, Australia · Not yet recruiting
Clinical Trial Site
Torquay, Victoria, Australia · Not yet recruiting
Clinical Trial Site
Auckland, New Zealand · Recruiting
Clinical Trial Site
Christchurch, New Zealand · Not yet recruiting
Clinical Trial Site
Nelson, New Zealand · Not yet recruiting
Clinical Trial Site
Rotorua, New Zealand · Not yet recruiting
Clinical Trial Site
Wellington, New Zealand · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.